AdventHealth

Running trials

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  NCT07237516· Source

• Recruiting

  Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

  NCT07231159· Source

• Recruiting

  Closed Loop and Education for Hypoglycemia Awareness Restoration

  NCT06325202· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  Individualizing Treatment for Asthma in Primary Care (Full Study)

  NCT07052942· Phase 4· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Source

• Recruiting

  Exploring the Potential of Robotic Telesurgery in Remote Settings

  NCT07130708· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Source

• Recruiting

  Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

  NCT06529822· Phase 1· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Source

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Source

• Enrolling by invitation

  Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

  NCT06560021· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Source

• Recruiting

  Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

  NCT06217302· Phase 3· Source

• Recruiting

  Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  NCT06511141· Source

• Recruiting

  Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

  NCT06401577· Source

• Recruiting

  PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

  NCT06617481· Phase 2· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Source

• Recruiting

  Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

  NCT05773144· Source

• Recruiting

  Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer

  NCT05789433· Source

• Recruiting

  A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

  NCT05512208· Phase 2· Source

• Recruiting

  A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  NCT05498428· Phase 2· Source

• Active, not recruiting

  A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

  NCT05142696· Phase 1/2· Source

• Recruiting

  Diabetes RElated to Acute Pancreatitis and Its Mechanisms

  NCT05197920· Source

• Active, not recruiting

  da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

  NCT04403022· Source

• Active, not recruiting

  A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

  NCT04036682· Phase 1/2· Source

• Active, not recruiting

  GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

  NCT04083599· Phase 1/2· Source

• Active, not recruiting

  Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

  NCT03992755· Phase 3· Source

• Active, not recruiting

  Destination Therapy Post Approval Study

  NCT03681210· Source

• Active, not recruiting

  A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  NCT03522246· Phase 3· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Source

• Active, not recruiting

  Multicenter Phase II Study of Transanal TME (taTME)

  NCT03144765· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

• Active, not recruiting

  Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)

  NCT02531607· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Source

• Active, not recruiting

  PRE-DETERMINE Cohort Study

  NCT01114269· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer6 recruiting
• Type 1 diabetes4 recruiting
• Lung cancer3 recruiting
• Cervical cancer2 recruiting
• Colorectal cancer2 recruiting
• Crohn's disease2 recruiting
• Heart failure2 recruiting
• Ovarian cancer2 recruiting
• Ulcerative colitis2 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Mirikizumab Real World Protocol

  NCT06696014· Source

• Terminated

  A Study of PHN-010 in Patients With Advanced Solid Tumors

  NCT06457997· Phase 1· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Source

• Withdrawn

  BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

  NCT05363644· Phase 3· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Source

• Recruiting

  Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  NCT05219617· Phase 3· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Source

• Completed

  Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System

  NCT05293639· Source

• Terminated

  BATwire Implant Kit Study

  NCT04600791· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Source

• Completed

  A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

  NCT03474107· Phase 3· Source

• Completed

  EUS-guided Ablation of Pancreatic Cyst Neoplasms

  NCT02422147· Source

• Completed

  Pediatric Obesity Weight Evaluation Registry (POWER) Study

  NCT02121132· Source

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· Source

• Completed

  BAROSTIM NEO Hypertension Pivotal Trial

  NCT01679132· Source

• Completed

  ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

  NCT01757665· Source

• Completed

  Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

  NCT01546987· Phase 3· Source

• Completed

  Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

  NCT00980954· Phase 3· Source

Trial sites

• AdventHealth1 trial
• AdventHealth2 trials
• AdventHealth39 trials
• Adventist Health System/Sunbelt1 trial
• Adventist Health System/Sunbelt, Inc.2 trials
• Florida Hospital14 trials
• Adventist Health System/Sunbelt,Inc1 trial